Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 40/100

Failure Rate

11.1%

1 terminated/withdrawn out of 9 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

33%

3 trials in Phase 3/4

Results Transparency

40%

2 of 5 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 1

4(50.0%)

Phase 3

3(37.5%)

Phase 2

1(12.5%)

8Total

Phase 1(4)

Phase 3(3)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06081062Phase 3Recruiting

Evaluate the Safety and Efficacy of Fabagal® (Agalsidase Beta) in Patients With Fabry Disease

Role: lead

NCT03552406Phase 1Unknown

Study of ISU104, Targeting ERBB3 in Patients With Advanced Solid Tumors

Role: lead

NCT04787887Phase 1Completed

A Phase I Study to Compare Abcertin and EU-sourced Cerezyme® in Healthy Volunteers

Role: lead

NCT03186677Phase 1Completed

Dose-escalation Study to Investigate the Safety, PK, and PD of ISU304/CB2679d in Hemophilia B Patients

Role: lead

NCT02770625Phase 3Completed

Phase III Study of ISU302 in Patients With Type 1 Gaucher Disease

Role: lead

NCT03087539Phase 2Unknown

Exploratory P2 Trial to Evaluate Efficacy and Safety of Clotinab® (Abciximab) in Acute MI Patients

Role: lead

NCT01161914Phase 3Withdrawn

The Safety and Efficacy Study of ISU302 in Patient With Type I Gaucher Disease

Role: lead

NCT02053896Completed

A Switch-Over Study of the Safety and Efficacy of ISU302 in Patients With Type 1 Gaucher Disease

Role: lead

NCT01881633Phase 1Completed

A Study of the Tolerability, Safety, and Pharmacokinetics of ISU302 in Healthy Volunteers

Role: lead

All 9 trials loaded